Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks.
Adults with no known immunity to sporozoites received, i.m., at weeks 0 and 8 two single 200 micrograms doses of a peptide Plasmodium falciparum sporozoite vaccine conjugated to tetanus toxoid ((NANP)3-TT) plus placebo (group 1) or interferon-alpha (IFN-alpha) (group 2) and were followed for antibody responses at weeks 4, 12 and 40. Peak antibody responses were observed at week 12. At week 40, a greater than or equal to 4-fold increase in antibody titre to sporozoites in IFA, or to (NANP)50 in ELISA was still detectable in 6 of 12 (50%) volunteers in group 1 and in 16 of 25 (64%) in group 2. Peak antibody titres in IFA and ELISA decreased with a rate of 0.8% and 0.5% per week, respectively.
Stürchler
D
D
Clinical Research Department, F. Hoffmann-La Roche & Co. Ltd, Basle, Switzerland.
Zimmer
G
G
Berger
R
R
Etlinger
H
H
Fernex
M
M
Matile
H
H
Just
M
M
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis* / Q000302:isolation & purification; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins / Q000276:immunology / Q000494:pharmacology*; D013745:Tetanus Toxoid / Q000276:immunology / Q000494:pharmacology*; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology*
D000913:Antibodies, Protozoan; D007370:Interferon Type I; D015800:Protozoan Proteins; D013745:Tetanus Toxoid; D014614:Vaccines, Synthetic; C065870:Ro 40-2361